Exisulind in the treatment of prostate cancer

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 101(Suppl. 10), 2371–2490 (2004).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Broering JM, Litwin MS et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J. Urol. 171(4), 1393–1401 (2004).
   PubMed Web of Science ®Google Scholar
• Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352(19), 1977–1984 (2005).
   PubMed Web of Science ®Google Scholar
• Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. [see comment]. N. Engl. J. Med. 347(11), 781–789 (2002).
   PubMedGoogle Scholar
• D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. [see comment]. Cancer 95(2), 281–286 (2002).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Moul J, Carroll PR et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J. Clin. Oncol. 21(11), 2163–2172 (2003).
   PubMed Web of Science ®Google Scholar
• Bott SR, Birtle AJ, Taylor CJ et al. Prostate cancer management: (1) an update on localised disease. Postgrad. Med. J. 79(936), 575–580 (2003).
   PubMedGoogle Scholar
• Ward JF, Blute ML, Slezak J et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J. Urol. 170(5), 1872–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Roach M III, DeSilvio M, Lawton C et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group [see comment]. J. Clin. Oncol. 21(10), 1904–1911 (2003).
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study), a Phase III randomised trial. Lancet 360(9327), 103–106 (2002).
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of Phase III RTOG 85–31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285–1290 (2005).
   PubMedGoogle Scholar
• D’Amico AV, Manola J, Loffredo M et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7), 821–827 (2004).
   PubMed Web of Science ®Google Scholar
• Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J. Urol. 172(5 Pt 2), S52–S57 (2004).
   Google Scholar
• Sato N, Akakura K, Isaka S et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64(2), 341–345 (2004).
   PubMedGoogle Scholar
• Amling CL, Bergstralh EJ, Blute ML et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 165(4), 1146–1151 (2001).
   PubMed Web of Science ®Google Scholar
• Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys. 37(5), 1035–1041 (1997).
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J. Urol. 162(2), 293–306 (1999).
   PubMed Web of Science ®Google Scholar
• Zhou P, Chen MH, McLeod D et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J. Clin. Oncol. 23(28), 6992–6998 (2005).
   PubMedGoogle Scholar
• Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr. Opin. Urol. 15(3), 187–195 (2005).
   PubMedGoogle Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Moore CN, George DJ. Update in the management of patients with hormone-refractory prostate cancer. Curr. Opin. Urol. 15(3), 157–162 (2005).
   PubMedGoogle Scholar
• Soh JW, Mao Y, Kim MG et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res. 6(10), 4136–4141 (2000).
   PubMed Web of Science ®Google Scholar
• Soh JW, Mao Y, Liu L et al. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK. J. Biol. Chem. 276(19), 16406–16410 (2001).
   PubMed Web of Science ®Google Scholar
• Thompson WJ, Piazza GA, Li H et al. Exisulind induction of apoptosis involves guanosine 3’,5’-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60(13), 3338–3342 (2000).
   PubMed Web of Science ®Google Scholar
• Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 17(25), 3277–3285 (1998).
   PubMed Web of Science ®Google Scholar
• Lim JT, Piazza GA, Pamukcu R et al. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin. Cancer Res. 9(13), 4972–4982 (2003).
   PubMedGoogle Scholar
• Lim JT, Piazza GA, Han EK et al. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. 58(7), 1097–1107 (1999).
   PubMed Web of Science ®Google Scholar
• Goluboff ET, Shabsigh A, Saidi JA et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53(2), 440–445 (1999).
   PubMed Web of Science ®Google Scholar
• Narayanan BA, Narayanan NK, Pittman B et al. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 10(22), 7727–7737 (2004).
   PubMed Web of Science ®Google Scholar
• Witta SE, Gustafson DL, Pierson AS et al. A Phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 10(21), 7229–7237 (2004).
   PubMed Web of Science ®Google Scholar
• Stoner GD, Budd GT, Ganapathi R et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv. Exper. Med. Biol. 470, 45–53 (1999).
   PubMed Web of Science ®Google Scholar
• van Stolk R, Stoner G, Hayton WL et al. Phase I trial of exisulind (sulindac sulfone FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 6(1), 78–89 (2000).
   PubMed Web of Science ®Google Scholar
• Goluboff ET. Exisulind, a selective apoptotic antineoplastic drug. Expert opin. Investig. Drugs 10(10), 1875–1882 (2001).
   PubMed Web of Science ®Google Scholar
• Jones SF, Kuhn JG, Greco FA et al. A Phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer. Clin. Lung Cancer 6(6), 361–366 (2005).
   PubMedGoogle Scholar
• Pusztai L, Zhen JH, Arun B et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J. Clin. Oncol. 21(18), 3454–3461 (2003).
   PubMedGoogle Scholar
• Goluboff ET, Prager D, Rukstalis D et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J. Urol. 166(3), 882–886 (2001).
   PubMed Web of Science ®Google Scholar
• Ryan CW, Stadler WM, Vogelzang NJ. A Phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. Br. J. Urol. Int. 95, 963–968 (2005).
   Google Scholar
• Blute ML, Bergstralh, EJ, Iocca A et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 165(1), 119–125 (2001).
   PubMed Web of Science ®Google Scholar